Browsing Tag
SpringWorks Therapeutics
2 posts
Merck KGaA’s $1.3bn Silence Therapeutics deal makes rare blood cancer a new growth priority
Merck KGaA has agreed to acquire Silence Therapeutics for approximately $1.3 billion in equity value, securing a clinical-stage gene-silencing platform and a promising treatment candidate for polycythemia vera as it expands its rare disease portfolio.
Merck KGaA to acquire SpringWorks Therapeutics in $3.9bn rare tumor expansion
Find out how Merck KGaA, Darmstadt, Germany’s $3.9 billion SpringWorks acquisition is reshaping rare tumor treatment and global healthcare leadership.